View Item 

Show simple item record

Efficacy of plasmapheresis on donor‐specific antibody reduction by HLA specificity in post–kidney transplant recipients
dc.contributor.authorYamada, Chisaen_US
dc.contributor.authorRamon, Daniel S.en_US
dc.contributor.authorCascalho, Mariliaen_US
dc.contributor.authorSung, Randall S.en_US
dc.contributor.authorLeichtman, Alan B.en_US
dc.contributor.authorSamaniego, Milagrosen_US
dc.contributor.authorDavenport, Robertson D.en_US
dc.date.accessioned2015-05-04T20:35:58Z
dc.date.available2016-05-10T20:26:28Zen
dc.date.issued2015-04en_US
dc.identifier.citationYamada, Chisa; Ramon, Daniel S.; Cascalho, Marilia; Sung, Randall S.; Leichtman, Alan B.; Samaniego, Milagros; Davenport, Robertson D. (2015). "Efficacy of plasmapheresis on donor‐specific antibody reduction by HLA specificity in post–kidney transplant recipients." Transfusion 55(4): 727-735.en_US
dc.identifier.issn0041-1132en_US
dc.identifier.issn1537-2995en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/111098
dc.publisherWiley Periodicals, Inc.en_US
dc.titleEfficacy of plasmapheresis on donor‐specific antibody reduction by HLA specificity in post–kidney transplant recipientsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/111098/1/trf12923.pdf
dc.identifier.doi10.1111/trf.12923en_US
dc.identifier.sourceTransfusionen_US
dc.identifier.citedreferenceSaghafi H, Rahbar K, Nobakht Haghighi A, et al. Efficacy of anti‐interleukin‐2 receptor antibody (daclizumab) in reducing the incidence of acute rejection after renal transplantation. Nephrourol Mon 2012; 4: 475 ‐ 477.en_US
dc.identifier.citedreferenceMitate E, Kawano S, Nakao Y, et al. Concurrence of autoantibodies to both laminin gamma1 and gamma2 subunits in a patient with kidney rejection response. Acta Derm Venereol 2013; 93: 114 ‐ 115.en_US
dc.identifier.citedreferenceIyer HS, Jackson AM, Zachary AA, et al. Transplanting the highly sensitized patient: trials and tribulations. Curr Opin Nephrol Hypertens 2013; 22: 681 ‐ 688.en_US
dc.identifier.citedreferenceKaposztas Z, Podder H, Mauiyyedi S, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23: 63 ‐ 73.en_US
dc.identifier.citedreferenceTzvetanov I, Spaggiari M, Joseph J, et al. The use of bortezomib as a rescue treatment for acute antibody‐mediated rejection: report of three cases and review of literature. Transplant Proc 2012; 44: 2971 ‐ 2975.en_US
dc.identifier.citedreferenceEverly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody‐ and cell‐mediated acute rejection. Transplantation 2008; 86: 1754 ‐ 1761.en_US
dc.identifier.citedreferenceWalsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor‐based primary therapy for antibody‐mediated renal allograft rejection. Transplantation 2010; 89: 277 ‐ 284.en_US
dc.identifier.citedreferenceWalsh RC, Alloway RR, Girnita AL, et al. Proteasome inhibitor‐based therapy for antibody‐mediated rejection. Kidney Int 2012; 81: 1067 ‐ 1074.en_US
dc.identifier.citedreferenceHao WJ, Zong HT, Cui YS, et al. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta‐analysis. Transplant Proc 2012; 44: 2955 ‐ 2960.en_US
dc.identifier.citedreferenceAtlani M, Sharma RK, Gupta A. Basiliximab induction in renal transplantation: long‐term outcome. Saudi J Kidney Dis Transpl 2013; 24: 473 ‐ 479.en_US
dc.identifier.citedreferencePonticelli C. Basiliximab: efficacy and safety evaluation in kidney transplantation. Expert Opin Drug Saf 2014; 13: 373 ‐ 381.en_US
dc.identifier.citedreferencevan den Hoogen MW, Hesselink DA, van Son WJ, et al. Treatment of steroid‐resistant acute renal allograft rejection with alemtuzumab. Am J Transplant 2013; 13: 192 ‐ 196.en_US
dc.identifier.citedreferenceStewart ZA, Collins TE, Schlueter AJ, et al. Case report: eculizumab rescue of severe accelerated antibody‐mediated rejection after ABO‐incompatible kidney transplant. Transplant Proc 2012; 44: 3033 ‐ 3036.en_US
dc.identifier.citedreferenceGoh BK, Chedid MF, Gloor JM, et al. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts. Transpl Immunol 2012; 27: 95 ‐ 100.en_US
dc.identifier.citedreferenceStegall MD, Chedid MF, Cornell LD. The role of complement in antibody‐mediated rejection in kidney transplantation. Nat Rev Nephrol 2012; 8: 670 ‐ 678.en_US
dc.identifier.citedreferenceHeeger PS. A complementary approach to treating antibody‐mediated transplant rejection. Kidney Int 2010; 78: 125 ‐ 127.en_US
dc.identifier.citedreferencePoirier N, Blancho G. Recombinant human C1‐inhibitor inhibits cytotoxicity induced by allo‐ and xenoantibodies. Transplant Proc 2008; 40: 581 ‐ 583.en_US
dc.identifier.citedreferenceBohmig GA, Wahrmann M, Regele H, et al. Immunoadsorption in severe C4d‐positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007; 7: 117 ‐ 121.en_US
dc.identifier.citedreferenceGenberg H, Kumlien G, Wennberg L, et al. The efficacy of antigen‐specific immunoadsorption and rebound of anti‐A/B antibodies in ABO‐incompatible kidney transplantation. Nephrol Dial Transplant 2011; 26: 2394 ‐ 2400.en_US
dc.identifier.citedreferenceZachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor‐specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66: 364 ‐ 370.en_US
dc.identifier.citedreferenceZachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal‐transplant patients. Transplantation 2003; 76: 1519 ‐ 1525.en_US
dc.identifier.citedreferenceRamos EJ, Pollinger HS, Stegall MD, et al. The effect of desensitization protocols on human splenic B‐cell populations in vivo. Am J Transplant 2007; 7: 402 ‐ 407.en_US
dc.identifier.citedreferenceDau PC. Increased antibody production in peripheral blood mononuclear cells after plasma exchange therapy in multiple sclerosis. J Neuroimmunol 1995; 62: 197 ‐ 200.en_US
dc.identifier.citedreferencePaglieroni T, Caggiano V, MacKenzie MR. Effects of plasmapheresis on peripheral blood mononuclear cell populations from patients with macroglobulinemia. J Clin Apher 1987; 3: 202 ‐ 208.en_US
dc.identifier.citedreferenceSadeghi M, Daniel V, Wang H, et al. Plasmapheresis adjusts inflammatory responses in potential kidney transplant recipients. Transplantation 2013; 95: 1021 ‐ 1029.en_US
dc.identifier.citedreferenceMayer L, Stohl W, Cunningham‐Rundles C. Feedback inhibition of B cell differentiation by monomeric immunoglobulin. Int Rev Immunol 1989; 5: 189 ‐ 195.en_US
dc.identifier.citedreferenceTawfik DS, Cowan KR, Walsh AM, et al. Exogenous immunoglobulin downregulates T‐cell receptor signaling and cytokine production. Pediatr Allergy Immunol 2012; 23: 88 ‐ 95.en_US
dc.identifier.citedreferenceChin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011; 30: 158 ‐ 163.en_US
dc.identifier.citedreferenceSutherland SM, Chen G, Sequeira FA, et al. Complement‐fixing donor‐specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012; 16: 12 ‐ 17.en_US
dc.identifier.citedreferenceTyan DB. New approaches for detecting complement‐fixing antibodies. Curr Opin Organ Transplant 2012; 17: 409 ‐ 415.en_US
dc.identifier.citedreferenceTait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non‐HLA antibodies in transplantation. Transplantation 2013; 95: 19 ‐ 47.en_US
dc.identifier.citedreferenceZwirner NW, Dole K, Stastny P. Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Hum Immunol 1999; 60: 323 ‐ 330.en_US
dc.identifier.citedreferenceAngaswamy N, Tiriveedhi V, Sarma NJ, et al. Interplay between immune responses to HLA and non‐HLA self‐antigens in allograft rejection. Hum Immunol 2013; 74: 1478 ‐ 1485.en_US
dc.identifier.citedreferenceZhang M, Lu FM, Qu LX, et al. Serum major‐histocompatibility‐complex class I‐related chain A antibody detection for the evaluation of graft dysfunction in renal allograft recipients. Chin Med J (Engl) 2011; 124: 2127 ‐ 2131.en_US
dc.identifier.citedreferenceBanasik M, Boratynska M, Koscielska‐Kasprzak K, et al. Long‐term follow‐up of non‐HLA and anti‐HLA antibodies: incidence and importance in renal transplantation. Transplant Proc 2013; 45: 1462 ‐ 1465.en_US
dc.identifier.citedreferenceQin Z, Lavingia B, Zou Y, et al. Antibodies against nucleolin in recipients of organ transplants. Transplantation 2011; 92: 829 ‐ 835.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
trf12923.pdf
Size:
104.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.